Progyny (NASDAQ:PGNY) Releases FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.790-1.820 for the period, compared to the consensus EPS estimate of 1.330. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Progyny also updated its Q4 2025 guidance to 0.370-0.400 EPS.

Progyny Price Performance

Progyny stock traded down $0.87 during mid-day trading on Thursday, hitting $18.01. 1,891,566 shares of the company’s stock traded hands, compared to its average volume of 1,640,581. The firm has a 50 day simple moving average of $20.94 and a two-hundred day simple moving average of $21.84. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $26.76. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of 30.53, a P/E/G ratio of 1.61 and a beta of 1.29.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.22). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. On average, research analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on PGNY shares. Truist Financial upped their price target on shares of Progyny from $24.00 to $27.00 and gave the company a “hold” rating in a research report on Thursday, July 17th. Canaccord Genuity Group upped their target price on Progyny from $21.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 20th. JPMorgan Chase & Co. lifted their target price on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Raymond James Financial set a $28.00 price target on Progyny in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.44.

Insider Buying and Selling at Progyny

In related news, EVP Allison Swartz sold 2,398 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the sale, the executive vice president owned 79,697 shares in the company, valued at approximately $1,829,843.12. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,895 shares of company stock worth $179,311. Corporate insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several institutional investors have recently added to or reduced their stakes in PGNY. California State Teachers Retirement System increased its stake in shares of Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares in the last quarter. Teza Capital Management LLC grew its stake in Progyny by 5.4% in the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares in the last quarter. Oxford Asset Management LLP grew its stake in Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares in the last quarter. Walleye Capital LLC raised its holdings in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after acquiring an additional 780 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Progyny during the second quarter worth $77,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.